Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — FY2016 Earnings Presentation
27 slides from Precigen's earnings presentation, Mar 1, 2017
Slide 1: Fourth Quarter and Full Year 2016 Financial Results and Business Update
March 1st, 2017 Fourth Quarter and Full Year 2016 Financial Results and Business Update Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: Marketable Products & Health
Marketable Products & Health Geno Germano – President
Slide 4: Oxitec, Arctic Apple and AquAdvantage Salmon 2016 developments
Oxitec – Scalable Friendly™ mosquito solution to suppress the disease-carrying Aedes aegypti Production at large scale facility began in Q4’2016 Expanded deployment in Piracicaba, Brazil Deployment began in Cayman Islands Received support from W.H.O., FDA and ANVISA Received significant consumer sup
Slide 5: Oxitec – 2017 Outlook
Expand current engagements in existing countries for Friendly™ Aedes including: Brazil – Expand into new states/cities/municipalities while continuing to work towards full ANVISA approval Cayman Islands – Expand to island-wide deployment on Grand Cayman India – Move from large cage to open field tri
Slide 6: Arctic Apple non-browning apples
Non-chemical, preservative-free approach to non-browning apples Three varieties approved to date: Arctic® Golden, Granny & Fuji Initial target market of fresh sliced apples is ~$500 million in U.S. Begin commercial sales of fresh sliced Arctic® apples in U.S. in Fall of 2017 Since introduction in th
Slide 7: AquAdvantage Salmon
AquAdvantage® Salmon Vaccine-free, antibiotic-free platform for fish farming No impact to marine environment & low carbon-footprint solution Salmon market exceeds $10 billion globally Atlantic salmon market in U.S. estimated at >$2 billion (~50% food service / ~50% direct retail) Almost all commerci
Slide 8: Development Platforms 2016 Developments
Development Platforms 2016 Developments: ZIOPHARM clinical and pre-clinical studies: Encouraging overall survival data in recurrent glioblastoma (GBM) Phase I study utilizing Ad-RTS-IL12, and promising pre-clinical results for Ad-RTS-IL-12 gene therapy in pediatric glioma Phase 1 trial of 2nd genera
Slide 9: 2017 Developments and Anticipated Milestones
2017 Developments: Oncology: Collaborator ZIOPHARM announced end-of-phase 2 meeting with FDA for Ad-RTS-hIL-12 in recurrent GBM and expects to announce meeting outcome in 1Q with goal of initiating a pivotal clinical trial in 2017 Oncology: Signed CRADA with NCI for development of immunotherapies fo
Slide 10: Gene/Cell Therapy programs by indication, phase and economics
Indication Gene/Cell Therapy Patient # Phase/IND XON Cost XON Economics Recessive Dystrophic EB FCX-007 1,000-2,500 P 1/2 0 14% Net Sales Pediatric Brain Tumors Ad-RTS-IL12 >3,000 IND 1H’2017 0 20% Op Profits Relapsed/Refractory AML Viral CD33+ CAR T ~2,000-8,000* IND 2017 0 20% Op Profits Recurrent
Slide 11: Existing Health Programs Utilizing Intrexon Technology
2013 Existing Health Programs Utilizing Intrexon Technology Development Platforms Additional Partnered Programs in Health Autoimmune & Inflammatory Diseases Type 1 Diabetes, GvHD, Arthritis, Celiac Cartilage Repair Off-The-Shelf Cells Human Infertility In vitro Egg Maturation Infectious Diseases Per
Slide 12: Divisions and Development Platforms
Divisions and Development Platforms Andrew Last, Ph.D. – Chief Operating Officer
Slide 13: Agricultural Biotech: Florian Gene Switch for Flowering Control
Agricultural Biotech Division Ag Bio: Florian™ Gene Switch for Flowering Control Florian™ Switch “On-off” gene switch to regulate timing of flowering, as well as selectively activate specific plant genes, through topical application of an activator Opens door to diverse range of beneficial agricultu
Slide 14: Agricultural Biotech: Regenerative Plant Cell Culture Platform
Agricultural Biotech Division Ag Bio: Regenerative Plant Cell Culture Platform High Throughput Plant Regeneration Crop A Published standard growth protocol Intrexon’s proprietary method Proprietary method to elicit genotype-independent pluripotent response in plant cells or tissues: Initial proof-of
Slide 15: Human Therapeutics: Gene Expression Control and Integration
Human Therapeutics Division HTD: Gene Expression Control and Integration Cellular expression of CAR and mbIL-15 following AttSite™ recombinase-mediated integration Sample Description % CAR+ Day 1 Day 8 Day 15 RTS-mbIL15 construct AttSite™ Recombinase 4.8 39.8 45.6 Promoterless mbIL15 negative contro
Slide 16: Human Therapeutics: pXoX Cardiac Platform
Human Therapeutics Division HTD: Gene Expression Control and Integration pXoX Control (pStuffer) Reversal of ADM Cardiomyopathy After Single Treatment pXoX+pRecombinase pXoX+pStuffer pXoX+pRecombinase pXoX+pStuffer pXoX+pRecombinase pXoX+pStuffer Proprietary pXoX platform represents first-ever multi
Slide 17: ActoBiotics Living Biofactories
IAD: ActoBiotics® Living Biofactories 3 6 I kDa Trefoil Factor 1 Interleukin-10 Human Proinsulin Human Proinsulin + hIL10 Peptide ‘X’ AG014 Reference Control Bioactivity 6 14 I kDa 17 28 I kDa I control I PINS Anti-TNF-alpha ActoBiotics® Oral Biotherapeutics Intrexon ActoBiotics Division ActoBiotics
Slide 18: Animal Sciences: Improving Tilapia Fillet Yield
ASD: Improving Tilapia Fillet Yield Tilapia is ranked within top 3 volume species in aquaculture; estimated global production greater than $2.5 billion Homozygous null (Hom) Tilapia demonstrate: Growth phenotype compared to wild type (WT) Increased fillet weight of 53% compared to WT Increased fille
Slide 19: Animal Sciences: EggPC Oocyte for Superior Bovine Genetics
ASD: EggPC Oocyte for Superior Bovine Genetics Animal Sciences Division Condensed Breakdown Separation Multiple cells identified after chemical induction Polar Body Germinal Vesicle 50µm 50µm 50µm 50µm 50µm 50µm Chromosomal Segregation Positive Brilliant Cresyl Blue Test Parthenogenesis Activation O
Slide 20: Genetic Toolbox Built for Methanotrophs
Intrexon’s Proprietary Genetic Toolbox Built for Methanotrophs Opens Door to Superior Platform for Industrial Fermentation of Valuable Fuels/Chemicals Methanotroph Genetic Tools 2014 Present DNA Transformation n/a ✔ DNA Integration & Marker Recycling n/a ✔ Multiple Plasmid Vectors n/a ✔ Multiple Pro
Slide 21: Industrial Products: Energy & Chemicals
Industrial Products Division IPD: Energy & Chemicals 0 10 20 30 Isobutanol TAM +$80B 2,3 BDO TAM +$10B Isobutyraldehyde TAM +$3B Yield Levels 2H’2016 Site Selection Level Toolbox Enabling Robust Design and Rapid Development of Valuable Molecules
Slide 22: Financial Overview
Financial Overview Joel Liffmann – Senior Vice President, Finance
Slide 23: Fourth Quarter Financial Performance
Fourth Quarter Financial Performance * Non-GAAP financial measure. Select Financial Highlights 4Q 2016 4Q 2015 Revenues $46.0 M $41.5 M Collaboration and Licensing Revenues $27.7 M $21.1 M Product & Services and Other Revenues $18.3 M $20.4 M Adjusted EBITDA $(5.8) M* $(12.9) M* Impact of change in
Slide 24: Financial Discipline
Financial Discipline We target at least 100% coverage of Annual Cash Operating Expenses as we build significant portfolio of backend commercial economics FY 2015 133% þ Q4 2016 61% þ FY 2016 129% þ *Cash consideration received for reimbursement of R&D services; **Total consideration received for tec
Slide 25: Portfolio Expansion & Maturation
Portfolio Expansion & Maturation December 2016 1 Over 30 January 2011 Collaborations December 2016 $17.5MM $391 Million January 2011 TAF and Received Milestones December 2016 $0 $193 Million January 2011 Cost Recovery Portfolio of Backend Economics Future Milestones & Royalties Financials
Slide 26: Summary
Summary Over 30 collaborations in place capitalizing on our leadership position in the engineering of biology Strong cash position with $243 million in cash, cash equivalents, and short and long-term investments, and equity securities and preferred stock valued at $153 million Developing high value
Slide 27: 4Q 2016 Financial Results and Business Update Q&A Session
4Q 2016 Financial Results and Business Update Q&A Session March 1st, 2017